Cidara Therapeutics, Inc. (CDTX) Research

Cidara Therapeutics, Inc. is a biotechnology company specializing in the creation, advancement, and commercialization of extended-duration anti-infective drugs. Their mission targets the prevention and treatment of infectious diseases and certain cancers within the U.S. Their primary therapeutic candidate, rezafungin acetate, is an innovative echinocandin antifungal designed to combat and avert severe fungal infections such as candidemia and invasive candidiasis, conditions known for their high fatality rates. Additionally, Cidara utilizes its Cloudbreak platform to engineer conjugated therapies aimed at preventing and treating influenza as well as various other viral illnesses, including respiratory syncytial virus (RSV), human immunodeficiency virus (HIV), and SARS-CoV-2, the pathogen behind COVID-19. Originally incorporated in 2012 as K2 Therapeutics, Inc., the company adopted its current name, Cidara Therapeutics, Inc., in July 2014. Its operations are headquartered in San Diego, California.

Market snapshot

Symbol
CDTX
Price
$221.38
Day change
0.00%
Market cap
$5.6B
P/E ratio
-18.63x
52-week range
15.22-221.42
Sector
Healthcare
Industry
Biotechnology
Analyst price target
$177.88

Peer companies

  • Adaptive Biotechnologies Corporation (ADPT)
  • Agios Pharmaceuticals, Inc. (AGIO)
  • Beam Therapeutics Inc. (BEAM)
  • Catalyst Pharmaceuticals, Inc. (CPRX)
  • IDEAYA Biosciences, Inc. (IDYA)
  • Disc Medicine, Inc. (IRON)
  • Legend Biotech Corporation (LEGN)
  • Mineralys Therapeutics, Inc. (MLYS)

Recent insider activity

  • RA CAPITAL MANAGEMENT, L.P. — M-Exempt (1286786 shares) on 2026-01-07
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (4652309 shares) on 2026-01-07
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (5079 shares) on 2026-01-07
  • RA CAPITAL MANAGEMENT, L.P. — M-Exempt (1286786 shares) on 2026-01-07
  • RA CAPITAL MANAGEMENT, L.P. — D-Return (22200 shares) on 2026-01-07

Open Cidara Therapeutics, Inc. (CDTX) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.